Literature DB >> 30915466

Risk of lung adenocarcinoma from smoking and radiation arises in distinct molecular pathways.

Noemi Castelletti1, Jan Christian Kaiser1, Cristoforo Simonetto1, Kyoji Furukawa2, Helmut Küchenhoff3, Georgios T Stathopoulos4,5.   

Abstract

KRAS mutations of lung adenocarcinoma (LADC) are associated with smoking but little is known on other exposure-oncogene associations. Hypothesizing that different inciting agents may cause different driver mutations, we aimed to identify distinct molecular pathways to LADC, applying two entirely different approaches. First, we examined clinicopathologic features and genomic signatures of environmental exposures in the large LADC Campbell data set. Second, we designed a molecular mechanistic risk model of LADC (M3LADC) that links environmental exposure to incidence risk by mathematically emulating the disease process. This model was applied to incidence data of Japanese atom-bomb survivors which contains information on radiation and smoking exposure. Grouping the clinical data by driver mutations revealed two main distinct molecular pathways to LADC: one unique to transmembrane receptor-mutant patients that displayed robust signatures of radiation exposure and one shared between submembrane transducer-mutant patients and patients with no evident driver mutation that carried the signature of smoking. Consistently, best fit of the incidence data was achieved with a M3LADC with two pathways: in one LADC risk increased with radiation exposure and in the other with cigarette consumption. We conclude there are two main molecular pathways to LADC associated with different environmental exposures. Future molecular measurements in lung cancer tissue of atom-bomb survivors may allow to further test quantitatively the M3LADC-predicted link of radiation to transmembrane receptor mutations. Moreover, the developed molecular mechanistic model showed that for low doses, as relevant e.g. for medical imaging, smokers have the same radiation risk compared with never smokers.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30915466     DOI: 10.1093/carcin/bgz036

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Club cells form lung adenocarcinomas and maintain the alveoli of adult mice.

Authors:  Rocio Sotillo; Georgios T Stathopoulos; Magda Spella; Ioannis Lilis; Mario Aa Pepe; Yuanyuan Chen; Maria Armaka; Anne-Sophie Lamort; Dimitra E Zazara; Fani Roumelioti; Malamati Vreka; Nikolaos I Kanellakis; Darcy E Wagner; Anastasios D Giannou; Vasileios Armenis; Kristina Am Arendt; Laura V Klotz; Dimitrios Toumpanakis; Vassiliki Karavana; Spyros G Zakynthinos; Ioanna Giopanou; Antonia Marazioti; Vassilis Aidinis
Journal:  Elife       Date:  2019-05-29       Impact factor: 8.140

2.  Collaborative efforts are needed among the scientific community to advance the adverse outcome pathway concept in areas of radiation risk assessment.

Authors:  Vinita Chauhan; Daniel Villeneuve; Donald Cool
Journal:  Int J Radiat Biol       Date:  2021-01-20       Impact factor: 2.694

3.  A bespoke health risk assessment methodology for the radiation protection of astronauts.

Authors:  Linda Walsh; Luana Hafner; Ulrich Straube; Alexander Ulanowski; Anna Fogtman; Marco Durante; Guillaume Weerts; Uwe Schneider
Journal:  Radiat Environ Biophys       Date:  2021-04-30       Impact factor: 1.925

4.  Mathematical modelling the pathway of genomic instability in lung cancer.

Authors:  Lingling Li; Xinan Zhang; Tianhai Tian; Liuyong Pang
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

5.  Identification of nine key genes by bioinformatics analysis for predicting poor prognosis in smoking-induced lung adenocarcinoma.

Authors:  Chuanli Ren; Weixiu Sun; Xu Lian; Chongxu Han
Journal:  Lung Cancer Manag       Date:  2020-04-27

Review 6.  Molecular epidemiology and diagnostics of KRAS mutations in human cancer.

Authors:  Jozsef Timar; Karl Kashofer
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

7.  mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability.

Authors:  Niklas Gremke; Pierfrancesco Polo; Aaron Dort; Jean Schneikert; Sabrina Elmshäuser; Corinna Brehm; Ursula Klingmüller; Anna Schmitt; Hans Christian Reinhardt; Oleg Timofeev; Michael Wanzel; Thorsten Stiewe
Journal:  Nat Commun       Date:  2020-09-17       Impact factor: 14.919

Review 8.  A Hidden Epidemic of "Intermediate Risk" Oropharynx Cancer.

Authors:  Vlad C Sandulache; David C Wilde; Erich M Sturgis; Elizabeth Y Chiao; Andrew G Sikora
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-10-17

9.  NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma.

Authors:  Yan Tang; Chunsheng Hu
Journal:  Dis Markers       Date:  2021-07-12       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.